4
MARKET OVERVIEW
Highlights the market structure, growth drivers, restraints, and near-term inflection points influencing performance.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
This section summarizes market dynamics, key shifts, and high-impact trends shaping demand outlook.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GENOMIC BIOMARKERS MARKET
5.5.1
AVERAGE SELLING PRICE TREND OF GENOMIC BIOMARKERS, BY PRODUCT, 2022-2024
5.5.2
AVERAGE SELLING PRICE OF GENOMIC BIOMARKERS, BY COUNTRY,
5.6.1
IMPORT SCENARIO FOR HS CODE 382200
5.6.2
EXPORT SCENARIO FOR HS CODE 382200
5.7
KEY CONFERENCES AND EVENTS, 2025–2026
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFF ON GENOMICS BIOMARKERS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.11.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
ADJACENT TECHNOLOGIES
6.2.1
ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)
6.2
SENSORS (WEARABLE DEVICES)
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.6
IMPACT OF AI/GEN AI ON GENOMIC BIOMARKERS MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
CASE STUDIES OF AI IMPLEMENTATION IN GENOMIC BIOMARKERS MARKET
6.6.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN GENOMIC BIOMARKERS MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8
GENOMICS BIOMARKERS MARKET, BY OFFERINGS, 2023-2030 (USD MILLION)
8.2.2
REAGENTS & CHEMICALS
9
GENOMICS BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
9.3.1
PREDICTIVE BIOMARKERS
9.3.1
SURROGATE BIOMARKERS
9.3.1
PHARMACODYNAMICS BIOMARKERS
9.3.1
PROGNOSTIC BIOMARKERS
10
GENOMICS BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
10.5
GENOMIC HYBRIDIZATION
11
GENOMICS BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
11.4
IMMUNOLOGICAL DISORDERS
11.5
NEUROLOGICAL DISORDERS
11.6
CARDIOVASCULAR DISORDERS
11.7
OTHER DISEASE INDICATION
12
GENOMICS BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
12.2
HOSPITALS & DIAGNOSTIC LABORATORIES
12.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.4
ACADEMIC & RESEARCH INSTITUTES
NOTE 5: OTHER END USERS INCLUDE CROS & CDMOS, MEDICAL DEVICE COMPANIES, AND FORENSIC LABS.
13
GENOMICS BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
13.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
13.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.6
REST OF ASIA PACIFIC
13.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.4
REST OF LATIN AMERICA
13.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2.2
KINGDOM OF SAUDI ARABIA
13.6.2.3
REST OF GCC COUNTRIES
13.6.3
REST OF MIDDLE EAST
13.7.1
MACROECONOMIC OUTLOOK FOR AFRICA
14.2
KEY PLAYERS STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS, 2022–2024
14.4
MARKET SHARE ANALYSIS,
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
REGION FOOTPRINT
14.5.5.2
OFFERING FOOTPRINT
14.5.5.3
TECHNOLOGY FOOTPRINT
14.5.5.4
APPLICATION FOOTPRINT
14.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
14.6.1
PROGRESSIVE COMPANIES
14.6.2
RESPONSIVE COMPANIES
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
14.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
14.7
COMPETITIVE SCENARIO
14.7.2
OTHER DEVELOPMENTS
14.8
BRAND/PRODUCT COMPARISON
14.9
COMPANY VALUATION AND FINANCIAL METRICS
15.1.1
THERMO FISHER SCIENTIFIC INC.
15.1.2
F. HOFFMANN-LA ROCHE LTD.
15.1.5
BIO-RAD LABORATORIES, INC.
15.1.6
AGILENT TECHNOLOGIES, INC.
15.1.7
EUROFINS SCIENTIFIC
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Genomic Biomarkers Market